Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:affects |
B cells
|
| gptkbp:associated_with |
gptkb:HIV/_AIDS
autoimmune diseases helicobacter pylori infection EBV infection |
| gptkbp:clinical_trial |
studying combination therapies
evaluating targeted therapies ongoing research for new treatments investigating CART-cell therapy testing new immunotherapies |
| gptkbp:end_of_life |
varies by stage
higher for localized disease lower for advanced disease |
| gptkbp:genetic_diversity |
BC L2 gene rearrangement
BC L6 gene mutation MYC gene alteration |
| https://www.w3.org/2000/01/rdf-schema#label |
B-cell lymphomas
|
| gptkbp:includes |
gptkb:Burkitt_lymphoma
follicular lymphoma diffuse large B-cell lymphoma mantle cell lymphoma |
| gptkbp:risk_factor |
age
weakened immune system certain infections exposure to chemicals |
| gptkbp:social_responsibility |
biopsy
imaging tests more common in men can be aggressive varies by subtype can be indolent incidence increases with age higher prevalence in certain geographic regions |
| gptkbp:symptoms |
weight loss
fever night sweats swollen lymph nodes |
| gptkbp:treatment |
gptkb:vaccine
radiation therapy chemotherapy stem cell transplant can be variable others may relapse some respond well to treatment |
| gptkbp:type |
gptkb:healthcare_organization
|
| gptkbp:type_of |
gptkb:non-Hodgkin_lymphoma
|
| gptkbp:bfsParent |
gptkb:Gammaherpesvirinae
gptkb:Tafasitamab |
| gptkbp:bfsLayer |
5
|